April 27, 2018 3:09 AM ET


Company Overview of Panacea Pharmaceuticals, Inc.

Company Overview

Panacea Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutic and diagnostic products for treatment of cancer and central nervous system diseases. The company focuses on developing novel proteins and biochemical pathways related to cellular regulation and cell cycle abnormalities in oncology, as well as neurodegenerative diseases such as stroke, Alzheimer's, Parkinson's disease, and chemotherapy-induced cognitive impairment/chemo-brain. Its products include PAN-22, a fully human anti-HAAH monoclonal antibody for the treatment of hepatocellular carcinoma; PAN-622, a toxin conjugate for the treatment of carcinoma of the bile duct; and PAN-811 for the treatment of ischemic s...

209 Perry Parkway

Suite 13

Gaithersburg, MD 20877

United States

Founded in 1999





Key Executives for Panacea Pharmaceuticals, Inc.

Co-Founder, Chairman of the Board, Chief Executive Officer, President and Chief Scientific Officer
Chief Operating Officer
Vice President of Medical & Clinical Affairs
Age: 65
Director of Clinical Laboratory Services
Compensation as of Fiscal Year 2017.

Panacea Pharmaceuticals, Inc. Key Developments

Panacea Pharmaceuticals Completes Enrollment in Phase 1 Study of First-In-Class Cancer Vaccine Therapy in Patients with Persistent Prostate Cancer

Panacea Pharmaceuticals announced the completion of patient enrollment in an open-label, parallel-designed, multi-center Phase 1 clinical trial of PAN-301-1 for the treatment of persistent prostate cancer to assess safety and immunogenicity. PAN-301-1 is a novel nanoparticle immunotherapy vaccine candidate targeting human aspartyl (asparaginyl) ß-hydroxylase (HAAH) also known as aspartate ß-hydroxylase (ASPH). In the Phase 1 trial, PAN-301-1 is being administered via intradermal injection in patients with biochemically relapsed prostate cancer, using a fixed dose-escalation schema every 21 days to establish the recommended Phase 2 dose. Twelve patients have been enrolled. A minimum of 3 doses of vaccine are administered to each subject. Based on this announced completion of study enrollment, the trial will conclude in the first half of 2018. Highlights of the initial safety and immunogenicity data to date are as follows: The PAN-301-1 therapeutic vaccine has been well tolerated with a highly favorable safety profile across all dose levels in the Phase 1 study; No drug-related adverse events or dose-limiting toxicities have been observed at any of the three vaccine dose levels evaluated; All subjects experienced dose-dependent HAAH-specific immune responses, including antibody levels in immunoassays and B-cell and T-cell responses; A majority of subjects treated beyond 3 months achieved a reduction in Prostate Specific Antigen (PSA) doubling rate (a measure of disease progression) and are receiving continued PAN-301-1 doses at the Investigator's discretion.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Panacea Pharmaceuticals, Inc., please visit panaceapharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.